A detailed history of Abound Wealth Management transactions in Genmab A/S stock. As of the latest transaction made, Abound Wealth Management holds 8 shares of GMAB stock, worth $163. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8
Previous 12 33.33%
Holding current value
$163
Previous $302,000 35.1%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$23.84 - $28.48 $95 - $113
-4 Reduced 33.33%
8 $196,000
Q4 2023

Aug 08, 2024

BUY
$27.94 - $35.44 $83 - $106
3 Added 33.33%
12 $383,000
Q2 2023

Aug 08, 2024

BUY
$37.4 - $42.94 $336 - $386
9 New
9 $343,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.5B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Abound Wealth Management Portfolio

Follow Abound Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abound Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Abound Wealth Management with notifications on news.